Evidence that brain-derived neurotrophic factor neuroprotection is linked to its ability to reverse the NMDA-induced inactivation of protein kinase C in cortical neurons

J Neurochem. 1999 Jan;72(1):102-11. doi: 10.1046/j.1471-4159.1999.0720102.x.

Abstract

Several lines of evidence indicate that a rapid loss of neuronal protein kinase C (PKC) activity is a characteristic feature of cerebral ischemia and is a necessary step in the NMDA-induced death of cultured neurons. Exposing embryonic day 18 primary rat cortical neurons to 50 microM NMDA or 50 microM glutamate for 10 min caused approximately 80% cell death over the next 24 h, but excitotoxic death was largely averted, i.e., by 70-80%, in cells pretreated with brain-derived neurotrophic factor (BDNF). An 8-h preexposure to BDNF (50-100 ng/ml) maximally protected cortical cells from the effects of NMDA and glutamate, although the transient application of BDNF between 8 and 4 h before NMDA was equally protective. These effects of BDNF were abolished at supralethal, i.e., >100 microM, NMDA concentrations. It is significant that BDNF pretreatment prevented the inactivation of PKC in cortical cells normally seen 30 min to 2 h following lethal NMDA or glutamate exposure. This BDNF effect did not arise from changes in NMDA channel activity because neither whole-cell NMDA current amplitudes nor increases in intracellular free Ca2+ concentration were altered by the 8-h BDNF pretreatment. Furthermore, BDNF offered no neuroprotection to cells treated with the PKC inhibitors staurosporine (10-20 nM), calphostin C (1-2.5 microM), or GF-109203X (100 nM) at the time of NMDA addition. These results underscore the importance of PKC inactivation in glutamate-induced neuronal death. They also suggest that BDNF neuroprotection arises, at least in part, via its ability to block the mechanism by which pathophysiological Ca2+ influx through the NMDA receptor causes membrane PKC inactivation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain-Derived Neurotrophic Factor / pharmacology*
  • Calcium / metabolism
  • Cerebral Cortex / cytology
  • Electrophysiology
  • Enzyme Inhibitors / pharmacology
  • Excitatory Amino Acid Agonists / pharmacology
  • Female
  • Glutamic Acid / toxicity
  • Indoles / pharmacology
  • Intracellular Signaling Peptides and Proteins*
  • Maleimides / pharmacology
  • Membrane Potentials / drug effects
  • Membrane Potentials / physiology
  • Membrane Proteins*
  • Myristoylated Alanine-Rich C Kinase Substrate
  • N-Methylaspartate / pharmacology
  • Neurons / chemistry
  • Neurons / drug effects
  • Neurons / enzymology*
  • Neuroprotective Agents / pharmacology*
  • Neurotoxins / metabolism
  • Phosphorylation
  • Pregnancy
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism*
  • Proteins / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, N-Methyl-D-Aspartate / physiology*
  • Staurosporine / pharmacology

Substances

  • Brain-Derived Neurotrophic Factor
  • Enzyme Inhibitors
  • Excitatory Amino Acid Agonists
  • Indoles
  • Intracellular Signaling Peptides and Proteins
  • Maleimides
  • Membrane Proteins
  • Neuroprotective Agents
  • Neurotoxins
  • Proteins
  • Receptors, N-Methyl-D-Aspartate
  • Myristoylated Alanine-Rich C Kinase Substrate
  • Glutamic Acid
  • N-Methylaspartate
  • Protein Kinase C
  • Staurosporine
  • bisindolylmaleimide I
  • Calcium